| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2013067036 |
| Title |
Direct Inhibitors of Keap1-Nrf2 Interaction As Antioxidant Inflammation Modulators. |
| Abstract |
A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keapl-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed. |
| Applicant(s) |
Rutgers, the State University of New Jersey the Broad Institute, Inc |
| Representative Drug(s) |
D02FWA |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2015092713 |
| Title |
Nrf2 Regulators. |
| Abstract |
The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators. |
| Applicant(s) |
Glaxosmithkline Intellectual Property Development Limited |
| Representative Drug(s) |
D0Q8JZ |
Drug Info
|
IC50(fluorescence polarization) < 10 nM |
[1] |
| China National Intellectual Property Administration (CNIPA) |
| Patent ID |
CN105566241 |
| Title |
1-Sulfonamido-4-Aryloxynaphthalene Compounds As Nrf2 Activators and Their Preparation, Pharmaceutical Compositions and Use In The Treatment of Diseases. |
| Applicant(s) |
China Pharmaceutical University |
| Representative Drug(s) |
D00TVL |
Drug Info
|
N.A. |
Click to Show More |
[1] |
|
2
|
D02JFV
|
Drug Info
|
N.A.
|
[1] |
|
3
|
D0LL7V
|
Drug Info
|
N.A.
|
[1] |
|
4
|
D0O3KN
|
Drug Info
|
N.A.
|
[1] |
